6K9 Stock Chart & Stats
€1.88
-€0.07(-6.42%)
At close: 4:00 PM EST
€1.88
-€0.07(-6.42%)
Day’s Range― - ―
52-Week Range€0.42 - €3.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€49.64M
Enterprise Value€195.14
Total Cash (Recent Filing)€54.53M
Total Debt (Recent Filing)€282.42K
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.94Price Target Upside162.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetDebt-to-equity near zero and roughly $52.2M of equity provide durable financial flexibility for multi-quarter clinical development. Low leverage reduces solvency risk and interest burden, supporting R&D spending and partnership options even as equity is gradually eroded by operating losses.
Positive Phase 1 CTIM-76 Data And Pipeline BreadthInterim Phase 1 efficacy and safety signals for CTIM-76, combined with a three-program T cell engager pipeline, materially de-risk early development. Durable impact: stronger clinical validation improves partner interest, enrollment prospects and long-term commercial optionality in the growing solid-tumor T cell engager space.
Full, Royalty-free Rights To Key Antibody AssetsAmendment granting irrevocable, royalty-free rights removes future milestone and royalty burdens and cancels termination risk. This structurally improves program economics and allows faster, unilateral development and partnering decisions, preserving upside and potential margins over the medium term.
Bears Say
Zero Revenue And Sustained Cash BurnThe company has no product revenue and reported widening TTM losses (~-$40.2M) with operating and free cash flow deeply negative (~-$32.8M TTM). This persistent cash burn forces reliance on external financing, heightening dilution risk and limiting strategic optionality for funding trials over the next several quarters.
Authorized Share Increase Raises Dilution RiskApproval to expand authorized shares to 300M structurally eases future equity issuance. While it facilitates capital raises for clinical programs, it also increases the likelihood and potential magnitude of shareholder dilution, weakening per-share economics and investor negotiating leverage over funding decisions.
Governance Issues And Litigation CostsCourt rulings invalidating charter provisions and the $850k mootness payment expose governance shortcomings and impose direct costs. Such episodes can distract management, invite future disputes, and reduce investor confidence, creating lasting reputational and oversight risks that may affect strategic execution.
Context Therapeutics News
6K9 FAQ
What was Context Therapeutics, Inc.’s price range in the past 12 months?
Context Therapeutics, Inc. lowest stock price was €0.42 and its highest was €3.12 in the past 12 months.
What is Context Therapeutics, Inc.’s market cap?
Context Therapeutics, Inc.’s market cap is €49.64M.
When is Context Therapeutics, Inc.’s upcoming earnings report date?
Context Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 21 days.
How were Context Therapeutics, Inc.’s earnings last quarter?
Context Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -€0.079 earnings per share for the quarter, beating the consensus estimate of -€0.097 by €0.018.
Is Context Therapeutics, Inc. overvalued?
According to Wall Street analysts Context Therapeutics, Inc.’s price is currently Undervalued.
Does Context Therapeutics, Inc. pay dividends?
Context Therapeutics, Inc. does not currently pay dividends.
What is Context Therapeutics, Inc.’s EPS estimate?
Context Therapeutics, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Context Therapeutics, Inc. have?
Context Therapeutics, Inc. has 91,879,170 shares outstanding.
What happened to Context Therapeutics, Inc.’s price movement after its last earnings report?
Context Therapeutics, Inc. reported an EPS of -€0.079 in its last earnings report, beating expectations of -€0.097. Following the earnings report the stock price went up 1.523%.
Which hedge fund is a major shareholder of Context Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:6K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Context Therapeutics, Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
6K9 Stock 12 Month Forecast
Average Price Target
€4.94
▲(162.91% Upside)